The Recall Desk

FDA (Drugs) recall action 69519

Oregon Compounding Centers, Inc. dba Creative Compounds recalled 56 products on 2014-11-12

The FDA (Drugs) publishes a recall like this one as 56 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 56 pages.

Products
56
Announced
2014-11-12
Critical
0
Units
348

Why these products were recalled

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection..

The agency’s own wording, quoted from the enforcement report.

The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.

States named across these recalls

51–56 of 56

  • SevereFDA (Drugs)··2014-11-12

    Hydroxyprogesterone Caproate Injectable Recalled for Sterility Assurance Concerns

    Oregon Compounding Centers is recalling Hydroxyprogesterone Caproate injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.

    Product
    HYDROXYPROGESTERONE CAPROATE (SESAME OIL), 250mg/mL, injectable, 5 mL glass vial, RX, Creative Compounds, Wilsonville, OR 97070
    Category
    Distribution
    2 states
  • SevereFDA (Drugs)··2014-11-12

    FDA Recalls Prednisolone Sodium Phosphate Eye Drops for Sterility Concerns

    Oregon Compounding Centers is recalling Prednisolone Sodium Phosphate ophthalmic drops due to quality control issues affecting sterility assurance.

    Product
    PREDNISOLONE Sodium Phosphate, 1%, Ophthalmic, 1 mL plastic dropper bottle, RX, Creative Compounds, Wilsonville, OR 97070
    Category
    Distribution
    2 states
  • SevereFDA (Drugs)··2014-11-12

    Vancomycin Injectable Syringes Recalled for Sterility Assurance Concerns

    Oregon Compounding Centers is recalling Vancomycin injectable syringes due to quality control issues affecting sterility assurance identified during an FDA inspection.

    Product
    VANCOMYCIN, 1mg/0.1mL, injectable, 0.2 mL plastic syringe, RX, Creative Compounds, Wilsonville, OR 97070
    Category
    Distribution
    2 states
  • SevereFDA (Drugs)··2014-11-12

    FDA Recalls Chorionic Gonadotropin Vials Due to Sterility Assurance Concerns

    Oregon Compounding Centers is recalling 117 vials of Chorionic Gonadotropin due to quality control issues affecting sterility assurance.

    Product
    CHORIONIC GONADOTROPIN, 5000 Units, sterile powder for reconstitution, glass vial, RX, Creative Compounds, Wilsonville, OR 97070
    Category
    Distribution
    2 states
  • SevereFDA (Drugs)··2014-11-12

    Gentamicin Sulfate Irrigation Solution Recalled for Sterility Assurance Concerns

    Creative Compounds is recalling Gentamicin Sulfate irrigation solution due to quality control issues affecting sterility assurance identified during an FDA inspection.

    Product
    GENTAMICIN SULFATE, 100mg/1000mL, solution for irrigation, 400 mL plastic bottle, RX, Creative Compounds, Wilsonville, OR 97070
    Category
    Distribution
    2 states